Hematologic Malignancy Clinical Trials in Milwaukee, Wisconsin

4 studies are recruiting for hematologic malignancy in Milwaukee, Wisconsin right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

   The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Froedtert & Medical College Clinics, Milwaukee, Wisconsin

   Locations

   45 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT06001788 on ClinicalTrials.gov

2. Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

   This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.

   Stage

   Not phased

   Ages

   Up to 30

   Site

   Children's Hospital of Wisconsin., Milwaukee, Wisconsin

   Locations

   6 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT06579469 on ClinicalTrials.gov

3. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Children's Hospital of Wisconsin, Milwaukee, Wisconsin

   Locations

   5 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

4. Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

   Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patie…

   Stage

   Phase 1

   Ages

   1 to 21

   Site

   Children's Hospital of Wisconsin, Milwaukee, Wisconsin

   Locations

   31 in total

   Run by

   Therapeutic Advances in Childhood Leukemia Consortium

   See if you can join NCT05476770 on ClinicalTrials.gov